Abstract:Fibroblast growth factor 9 (Fgf9) is a well-known factor that regulates bone development; however, its function in bone homeostasis is still unknown. Previously, we identified a point mutation in the FGF9 gene (p.Ser99Asn, S99N) and generated an isogeneic knock-in mouse model, which revealed that this loss-of-function mutation impaired early joint formation and was responsible for human multiple synostosis syndrome 3 (SYNS3). Moreover, newborn and adult S99N mutant mice exhibited significantly increased bone mass, suggesting that Fgf9 also participated in bone homeostasis. Histomorphology, tomography, and serological analysis of homozygous newborns and heterozygous adults showed that the Fgf9S99N mutation immensely increased bone mass and bone formation in perinatal and adult bones and decreased osteoclastogenesis in adult bone. An in vitro differentiation assay further revealed that the S99N mutation enhanced bone formation by promoting osteogenesis and mineralization of bone marrow mesenchymal stem cells (BMSCs) and attenuating osteoclastogenesis of bone marrow monocytes (BMMs). Considering the loss-of-function effect of the S99N mutation, we hypothesized that Fgf9 itself inhibits osteogenesis and promotes osteoclastogenesis. An in vitro differentiation assay revealed that Fgf9 prominently inhibited BMSC osteogenic differentiation and mineralization and showed for the first time that Fgf9 promoted osteoclastogenesis by enhancing preosteoclast aggregation and cell-cell fusion. Furthermore, specific inhibitors and in vitro differentiation assays were used and showed that Fgf9 inhibited BMSC osteogenesis mainly via the MEK/ERK pathway and partially via the PI3K/AKT pathway. Fgf9 also promoted osteoclastogenesis as a potential costimulatory factor with macrophage colony-stimating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) by coactivating the MAPK and PI3K/AKT signaling pathways. Taken together, our study demonstrated that Fgf9 is a negative regulator of bone homeostasis by regulating osteogenesis and osteoclastogenesis and provides a potential therapeutic target for bone degenerative diseases. © 2020 American Society for Bone and Mineral Research (ASBMR).

Fgf9 Negatively Regulates Bone Mass by Inhibiting Osteogenesis and Promoting Osteoclastogenesis Via MAPK and PI3K/AKT Signaling.

Fgf9 regulates bone marrow mesenchymal stem cell fate and bone-fat balance in osteoporosis by PI3K/AKT/Hippo and MEK/ERK signaling

Gα13 Negatively Controls Osteoclastogenesis Through Inhibition of the Akt-GSK3β-NFATc1 Signalling Pathway

Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells

Fibroblast Growth Factor 9 (Fgf9) Negatively Regulates The Early Stage Of Chondrogenic Differentiation

The Role of FGF9 and FGFR3 on Bone Development and Disorders

Autoinhibitory Mechanism for the Mutation-Induced Impaired FGF9 Signaling.

Fgfr1 deficiency in osteocytes leads to increased bone mass by enhancing Wnt/β-catenin signaling

Effect of Fibroblast Growth Factor 9 on the Osteogenic Differentiation of Bone Marrow Stromal Stem Cells and Dental Pulp Stem Cells

The G9a histone methyltransferase represses osteoclastogenesis and bone resorption by regulating NFATc1 function

MiR-9-1 controls osteoblastic regulation of lymphopoiesis

The Fundamentals of Fibroblast Growth Factor 9.

A point mutation in Fgf9 impedes joint interzone formation leading to multiple synostoses syndrome

FGF2 positively regulates osteoclastogenesis via activating the ERK-CREB pathway

The Effect of Fibroblast Growth Factor 9 on the Osteogenic Differentiation of Calvaria-Derived Mesenchymal Cells.

A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development

Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene.

1625-P: Osteoprotection by FNIP1 Signaling in Skeletal Muscle

Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-β signaling pathway

Fibroblast Growth-Factor Receptor-3 Is A Negative Regulator Of Bone-Growth And Development

Skeletal dysmorphology and mineralization defects in Fgf20 KO mice